GlassScriptPhysician profile
Kenneth A Redon
NPI 1528531274
$4,386.03
in general payments reported to CMS, 2019-2025
22 companies · $877 in 2025
The $877 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,417 · 2022: $768 · 2023: $244 · 2024: $1,081 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,314.64 | 2021-2025 | |
| Novo Nordisk INC | $1,158.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Aimmune Therapeutics, INC. | $515.35 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $292.74 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $181.49 | 2021-2024 | Farxiga, Airsupra |
| Corcept Therapeutics | $143.75 | 2022-2025 | Korlym |
| Glaxosmithkline, LLC. | $124.70 | 2022 | |
| Medtronic, INC. | $110.65 | 2024 | Intellis Adaptivestim |
| Viiv Healthcare Company | $86.24 | 2025 | Apretude |
| Nestle Healthcare Nutrition INC. | $81.20 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.56 | 2021-2025 | Jardiance, Synjardy |
| Electromed, INC. | $59.76 | 2021 | |
| Mannkind Corporation | $38.97 | 2021 | |
| Dexcom, INC. | $33.44 | 2021-2022 | |
| Hologic Sales and Service, LLC | $30.86 | 2024 | Aptima |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.87 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $22.71 | 2023 | Prolia, Evenity |
| Lundbeck LLC | $20.73 | 2024 | Rexulti |
| Abiomed | $20.57 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $18.22 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.51 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.56 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Redon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.